Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07389590 · ClinicalTrials.gov registry record · Phase 4
Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis
A Phase 4 study, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
NCT07389590: Recruiting Phase 4 study, sponsored by Johns Hopkins University.
NCT07389590 is a Phase 4 study that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 50 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07389590, a Phase 4 study, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
Study Summary
The proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or delay this phenomenon.
Interventions
- DRUG Ublituximab
- DRUG Ocrelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-02-10 |
| Est. Completion | 2029-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07389590
The ClinicalTrials.gov registry entry for NCT07389590 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ublituximab is the first listed.
NCT07389590 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07389590 about?
NCT07389590 is a clinical study titled "Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis". The proposed study is a pilot study of ublituximab involving people with multiple sclerosis (MS) who are experiencing a "wearing off" phenomenon (return or worsening of MS-related symptoms) while being treated with ocrelizumab, and exploring whether switching to ublituzimab can resolve, improve or d...
What is the current status of trial NCT07389590?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2026-02-10. Estimated completion is 2029-03.
What interventions are being tested in trial NCT07389590?
The interventions under investigation include: Ublituximab (DRUG), Ocrelizumab (DRUG).
Who is sponsoring clinical trial NCT07389590?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.